Literature DB >> 20145269

Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.

Meinolf Suttorp, Christian Thiede, Josephine T Tauer, Ursula Range, Brigitte Schlegelberger, Nils von Neuhoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20145269      PMCID： PMC2864398          DOI： 10.3324/haematol.2009.019224

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.

Authors:  Hansjoerg Schmid; Bernadette A S Jaeger; Judith Lohse; Meinolf Suttorp
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

2.  Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.

Authors:  Sofia Jönsson; Bob Olsson; Claes Ohlsson; Mattias Lorentzon; Dan Mellström; Hans Wadenvik
Journal:  Haematologica       Date:  2008-05-27       Impact factor: 9.941

3.  Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

Authors:  F Millot; J Guilhot; B Nelken; T Leblanc; E S De Bont; A N Békassy; H Gadner; S Sufliarska; J Stary; H Gschaidmeier; F Guilhot; M Suttorp
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

4.  Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

5.  Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

Authors:  Martin A Champagne; Renaud Capdeville; Mark Krailo; Wenchun Qu; Bin Peng; Marianne Rosamilia; Martine Therrien; Ulrike Zoellner; Susan M Blaney; Mark Bernstein
Journal:  Blood       Date:  2004-07-01       Impact factor: 22.113

Review 6.  Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.

Authors:  M Suttorp
Journal:  Bone Marrow Transplant       Date:  2008-10       Impact factor: 5.483

Review 7.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

8.  Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia.

Authors:  Ronald Adler; Susanne Viehmann; Eberhard Kuhlisch; Yvonne Martiniak; Silja Röttgers; Jochen Harbott; Meinolf Suttorp
Journal:  Eur J Haematol       Date:  2008-11-10       Impact factor: 2.997
  8 in total
  2 in total

1.  Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

Authors:  Nobuko Hijiya; Kirk R Schultz; Markus Metzler; Frederic Millot; Meinolf Suttorp
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

Review 2.  Management of chronic myeloid leukemia in childhood.

Authors:  Meinolf Suttorp; Louise Eckardt; Josephine Tabea Tauer; Frederic Millot
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.